In a report published by Morgan Stanley, Pfizer's PFE early generic Lipitor risk is explained and quantified.
Morgan Stanley said that Mylan filed a lawsuit to compel FDA to act on generic Lipitor. “Mylan believes that FDA should deny Ranbaxy's exclusivity if FDA invoked its Application Integrity Policy against Ranbaxy's Lipitor application. Mylan's lawsuit states that FDA has not responded to repeated requests to discuss the matter, and it is attempting to compel FDA to approve its generic Lipitor in June '11. We estimate $0.11 (5%) downside risk to our 2011E of $2.23 if Mylan succeeds.”
Pfizer closed yesterday at $20.18.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in